A Phase 3 interventional study of FSH (Follicle Stimulating Hormone) in Oocyte Donation, sponsored by IBSA Institut Biochimique SA. Completed at 1 site in Spain. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-09.
Sponsored by IBSA Institut Biochimique SA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to evaluate immunogenic potential of FSH-IBSA in healthy volunteers undergoing controlled ovarian hyperstimulation (COH) in an oocyte donation program.
IBSA Institut Biochimique SA is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FSH (Follicle stimulation hormone, 75 IU/vial) will be administered to women according to their need and response assessed by the Investigator.
Drug: FSH (Follicle Stimulating Hormone)
Number of Patients Producing Anti-FSH Antibodies.
The immunogenicity potential of FSH in healthy volunteer will be assessed by analysing serum samples collected at different timepoints during two treatment cycle for oocytes donation: cycle 1, serum samples will be collected before treatment start (baseline), after 7-13 days and after 28 days of treatment; Cycle 2: serum samples will be collected before starting the second cycle (baseline 2), after 7-13 days and after 28 days of treatment. Cycle 1 and cycle 2 will be separated by a wash-out period of two months.
Time frame: 4 months.
Number of Oocytes Retrieved
the number of oocytes retrieved in the first cycle and in the second cycle are compared.
Time frame: after 2 weeks of treatment
Total Dose of FSH Units Used.
Time frame: after 2 weeks of treatment
| Milestone | Follicle Stimulation Hormone |
|---|---|
| Started | 27 |
| Completed | 24 |
| Not completed | 3 |
The immunogenicity potential of FSH in healthy volunteer will be assessed by analysing serum samples collected at different timepoints during two treatment cycle for oocytes donation: cycle 1, serum samples will be collected before treatment start (baseline), after 7-13 days and after 28 days of treatment; Cycle 2: serum samples will be collected before starting the second cycle (baseline 2), after 7-13 days and after 28 days of treatment. Cycle 1 and cycle 2 will be separated by a wash-out period of two months.
| participants | Follicle Stimulationg Hormone |
|---|---|
| Number of Patients Producing Anti-FSH Antibodies. | 0 |
the number of oocytes retrieved in the first cycle and in the second cycle are compared.
| oocytes | First Cycle | Second Cycle |
|---|---|---|
| Number of Oocytes Retrieved | 13.4 ± 7.7 | 15.7 ± 7.8 |
| IU | First Cycle | Second Cycle |
|---|---|---|
| Total Dose of FSH Units Used. | 1911.1 ± 604.8 | 1984.4 ± 622.4 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Follicle Stimulating Hormone | — | 1/27 (3.7%) | 7/27 (25.9%) |
| Event | Follicle Stimulating Hormone |
|---|---|
| HaemorrhageInjury, poisoning and procedural complications | 1/27 |
| Event | Follicle Stimulating Hormone |
|---|---|
| HeadhacheNervous system disorders | 3/27 |
| abdominal painGastrointestinal disorders | 1/27 |
| PirexiaGeneral disorders | 1/27 |
| bacterial vaginosisInfections and infestations | 1/27 |
| candida infectionInfections and infestations | 1/27 |
| lymp injuryInjury, poisoning and procedural complications | 1/27 |
| Back painMusculoskeletal and connective tissue disorders | 1/27 |
| Muscle spasmMusculoskeletal and connective tissue disorders | 1/27 |
| DizzinessNervous system disorders | 1/27 |
All the subjects that started the stimulation.
| Age, Continuous(years) | Follicle Stimulating Hormone |
|---|---|
| Mean | 25.7 ± 5.4 |
| Gender(Participants) | Follicle Stimulating Hormone |
|---|---|
| Female | 27 |
| Male | 0 |
| Race (NIH/OMB)(Participants) | Follicle Stimulating Hormone |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 27 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| BMI (kg/m2)(kg/m2) | Follicle Stimulating Hormone |
|---|---|
| Mean | 21.7 ± 2.0 |
The record gives a start of Mar 2013, a primary completion of Jul 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follicle Stimulating Hormone
IBSA Institut Biochimique SA →